Clinical trialObsActive not recruiting
A Registry for BRCA Mutation Carriers With Pancreatic Ductal Adenocarcinoma
- Outcome
- Ongoing
- Phase
- Obs
- Status
- Active not recruiting
- Study type
- Observational
- Start
- 4 November 2013
- Expected end
- November 2026
- Enrollment
- 600 participants
- Sites
- 13
- Primary outcomes
- prospective Registry
- Sponsor
- Other
- Results posted
- No
- Last update
- 30 December 2025
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The purpose of this study is to better understand why pancreatic cancer develops in some people who are known carriers of the gene mutation (an abnormality) called BRCA, or its close relative PALB2. The investigators hope to do this by establishing a BRCA/PALB2 mutation carriers Pancreatic Ductal Adenocarcinoma (the common form of pancreatic cancer) Registry. A registry is a database of information.